All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Special Protocol Assessment to Phase III Ublituximab/Ibrutinib Study

September 21st 2014

TG Therapeutics has reached an agreement with the FDA regarding a Special Protocol Assessment for a phase III clinical trial exploring ublituximab in combination with ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

PREVAIL Trial Investigator Discusses Pre-Chemo Enzalutamide Indication

September 20th 2014

Last week, the FDA expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

Novel Therapies on the Horizon in AML

September 18th 2014

Treatment advancements for patients with acute myeloid leukemia (AML) are few and far between with marginal gains being made in the form of changes in current standard therapies or supportive care.

Pertuzumab Use Continues to Expand in Breast Cancer

September 17th 2014

Treatment strategies that incorporate pertuzumab (Perjeta) continue to evolve as more clinical trial data becomes available.

Differences Identified Between What Medicare Covers and What Patients with Cancer Want

September 15th 2014

Does Medicare coverage for patients with cancer match up to what they actually want covered? There appears to be a mismatch between covered benefits and beneficiary preferences that involves quality of life and financial burden of care, according to a study from Duke University.

UCLA Researcher Provides Insight Into the Impact of Pembrolizumab in Melanoma

September 13th 2014

To gain further insight into the approval of pembrolizumab, OncLive interviewed John Glaspy, MD, MPH, from the Jonsson Comprehensive Cancer Center at UCLA, where research into the novel drug was conducted.

Ramucirumab Improves Survival in mCRC

September 12th 2014

The combination of ramucirumab and FOLFIRI significantly improved OS and PFS compared with chemotherapy alone as a second-line treatment for patients with mCRC.

More Hospital-Based Cancer Programs Offering Patient Financial Advocacy Services

September 11th 2014

Increasingly, payers and patients are demanding that hospital-based oncology practices take a patient-centered approach in delivering care, with a specific focus on offering some form of financial assistance services to their patients, according to findings from the Association of Community Cancer Centers' "2014 Trends in Cancer Programs" survey.

FDA Approves Pre-Chemo Enzalutamide for mCRPC

September 10th 2014

The FDA has expanded the approval for enzalutamide to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

Oncologist Data from a New Survey Addresses the Emotional Impact of Treating Advanced Breast Cancer

September 10th 2014

Data from a brand new survey addressed some of the emotional issues faced by physicians when treating and delivering a diagnosis of advanced breast cancer.

Rosenberg Sees New Milestone in Latest CAR Findings

September 9th 2014

Steven A. Rosenberg, MD, PhD, discusses the implications of responses to the CAR T-cell therapy KTE-C19, particularly among patients with chemotherapy-refractory diffuse large B-cell lymphomas.

New ASCO/CCO mCRPC Treatment Guideline Incorporates Latest Approved Drugs

September 8th 2014

ASCO and CCO have released an updated guideline focused on the treatment of men with mCRPC that incorporates information about 6 recently approved drugs that have significantly changed the therapeutic landscape.

Two Webinars Address Oncology Bundled Payments

September 8th 2014

Don't look now but a consensus that bundled payments is the best payment reform strategy is emerging, and it's expected that many pilot and demonstration projects will start soon.

Bristol-Myers Squibb Challenges Patent on Merck's Pembrolizumab

September 5th 2014

BMS has filed a lawsuit over Merck's newly approved immunotherapy drug pembrolizumab, contending that the much-heralded PD-1 inhibitor will infringe upon patents that Bristol-Myers holds on the groundbreaking technology.

FDA Approves Pembrolizumab for Advanced Melanoma

September 4th 2014

The FDA has approved pembrolizumab (Keytruda) as a treatment for patients with advanced or unresectable melanoma who are no longer responding to other drugs, making it the first PD-1 inhibitor to gain approval in the United States.

Four Distinct Subtypes of Gastric Cancer Found

September 4th 2014

Gastric cancer is comprised of 4 distinct molecular subtypes of disease, each representing a unique opportunity for new drug development, according to a paper published in Nature by The Cancer Genome Atlas (TCGA).

Converting From Manual to Electronic Transactions Could Save Healthcare Industry Billions

September 4th 2014

A report issued by the Council for Affordable Quality Healthcare (CAQH) suggests that if providers and health plans converted fully from manual to electronic transactions, it could result in an additional estimated savings of $8.1 billion for the healthcare industry.

FDA Grants Priority Review to Lanreotide for GEP NETs

September 3rd 2014

The FDA has assigned a priority review designation to lanreotide (Somatuline Depot) as a treatment for patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)

ASCO Issues New Guideline for Advanced HER2-Negative Breast Cancer

September 3rd 2014

The American Society of Clinical Oncology (ASCO) has released a new clinical practice guideline on the treatment of patients with advanced HER2-negative breast cancer.

Negative Cabozantinib Prostate Study Triggers Massive Exelixis Restructuring

September 2nd 2014

Cabozantinib (Cometriq) failed to significantly extend overall survival compared with prednisone as a treatment for men with metastatic castration-resistant prostate cancer.